PE20151434A1 - Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo - Google Patents

Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo

Info

Publication number
PE20151434A1
PE20151434A1 PE2015000538A PE2015000538A PE20151434A1 PE 20151434 A1 PE20151434 A1 PE 20151434A1 PE 2015000538 A PE2015000538 A PE 2015000538A PE 2015000538 A PE2015000538 A PE 2015000538A PE 20151434 A1 PE20151434 A1 PE 20151434A1
Authority
PE
Peru
Prior art keywords
methods
heart failure
reduction
reduce
risks
Prior art date
Application number
PE2015000538A
Other languages
English (en)
Inventor
D Travis Wilson
Hani N Sabbah
Original Assignee
Stealth Peptides Int Inc
Henry Ford Health Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides Int Inc, Henry Ford Health Systems filed Critical Stealth Peptides Int Inc
Publication of PE20151434A1 publication Critical patent/PE20151434A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)

Abstract

Se refiere a metodos que comprenden la administracion a un sujeto de una cantidad efectiva de un peptido aromatico cationico para reducir los niveles de proteina C reactiva, factor de necrosis tumoral alfa, interleuquina 6, especies reactivas del oxigeno, Nt-pro BNP, y/o troponina cardiaca I, y/o reducir los niveles de expresion de MLCL AT1 y/o ALCAT 1 en sujetos que necesitan de un tratamiento para la insuficiencia cardiaca.
PE2015000538A 2012-10-22 2013-10-22 Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo PE20151434A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US201361839743P 2013-06-26 2013-06-26
US201361839750P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
PE20151434A1 true PE20151434A1 (es) 2015-10-16

Family

ID=50545459

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000538A PE20151434A1 (es) 2012-10-22 2013-10-22 Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo

Country Status (13)

Country Link
US (3) US20150246092A1 (es)
EP (4) EP2908839B1 (es)
JP (3) JP2016503397A (es)
KR (1) KR20160009008A (es)
CN (2) CN105050613A (es)
AU (2) AU2013334788A1 (es)
BR (1) BR112015009072A2 (es)
CA (1) CA2889155A1 (es)
HK (1) HK1213799A1 (es)
MX (1) MX2015005102A (es)
NI (1) NI201500057A (es)
PE (1) PE20151434A1 (es)
WO (1) WO2014066419A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110339339A (zh) 2013-03-01 2019-10-18 康德生物医疗技术公司 治疗线粒体疾病的方法
JP6518197B2 (ja) 2013-03-01 2019-05-22 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
EP3474877A4 (en) * 2016-06-24 2019-11-27 University of Southern California MENTSH ANALOGUE AS THERAPEUTICS FOR DIABETES, ADIPOSITAS AND ASSOCIATED DISEASES AND COMPLICATIONS THEREOF
AU2018214554C1 (en) * 2017-02-01 2022-12-15 Novo Nordisk A/S Treatment of diuretic resistance
JP7395479B2 (ja) 2018-01-05 2023-12-11 ノヴォ ノルディスク アー／エス 免疫抑制なしにｉｌ－６媒介性炎症を処置する方法
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
KR20150043568A (ko) * 2002-07-19 2015-04-22 애브비 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료
HUE027110T2 (en) * 2003-02-04 2016-08-29 Cornell Res Foundation Inc Use of an aromatic cationic peptide
EP1890153A1 (en) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
EP2262520B1 (en) * 2008-02-26 2017-05-03 Cornell University Compositions for prevention and treatment of renal injury
EP3251686A1 (en) * 2009-08-12 2017-12-06 Cornell University Methods for preventing or treating metabolic syndrome
JP2013506696A (ja) * 2009-10-05 2013-02-28 コーネル ユニヴァーシティー 心不全の予防又は処置の方法
MX2012005927A (es) * 2009-11-24 2012-11-23 Alder Biopharmaceuticals Inc Anticuerpos para il-6 uso de los mismos.
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHODS OF REALIZING AORTO-CORONARY BRIDGE
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
US20130040901A1 (en) * 2010-02-26 2013-02-14 University Of Florida Research Foundation Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP3300740A1 (en) * 2012-08-02 2018-04-04 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
EP2928562A4 (en) * 2012-12-06 2016-06-22 Stealth Peptides Int Inc PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2916497C (en) * 2013-06-26 2022-07-12 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression

Also Published As

Publication number Publication date
BR112015009072A2 (pt) 2017-07-04
US20150246092A1 (en) 2015-09-03
MX2015005102A (es) 2016-02-09
EP4397314A1 (en) 2024-07-10
EP2908839A2 (en) 2015-08-26
EP3586862B1 (en) 2021-12-08
AU2018206766A1 (en) 2018-08-09
CN110193077A (zh) 2019-09-03
JP2016503397A (ja) 2016-02-04
EP4005582A1 (en) 2022-06-01
EP2908839A4 (en) 2016-06-15
NI201500057A (es) 2015-07-16
AU2013334788A1 (en) 2015-06-04
US20230190859A1 (en) 2023-06-22
CN105050613A (zh) 2015-11-11
EP2908839B1 (en) 2019-08-21
JP2019194193A (ja) 2019-11-07
CA2889155A1 (en) 2014-05-01
EP3586862A1 (en) 2020-01-01
WO2014066419A3 (en) 2014-06-12
US20200360462A1 (en) 2020-11-19
WO2014066419A2 (en) 2014-05-01
KR20160009008A (ko) 2016-01-25
HK1213799A1 (zh) 2016-07-15
JP2018109012A (ja) 2018-07-12

Similar Documents

Publication Publication Date Title
PE20151434A1 (es) Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2016000373A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
CR20150149A (es) Proteínas de fusión para el tratamiento de un síndrome metabólico
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
CL2015003199A1 (es) Peptidos terapeuticos
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
CL2008003476A1 (es) Variante del peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; y su uso para tratar una displasia del esqueleto o un trastorno de la musculatura lisa vascular.
EA201291234A1 (ru) Аналоги глюкагона
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
MX2018015089A (es) Combinacion de linagliptina y metformina.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
EA201992562A1 (ru) Пептиды для лечения сахарного диабета
CR20150324A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
ECSP099828A (es) Uso de ranolazina para peptido natriuretico tipo-cerebral elevado
CO2019003865A2 (es) Proteína terapéutica
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.
PE20221463A1 (es) Celula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal